Lumos Pharma Inc - Company Profile

Powered by

All the data and insights you need on Lumos Pharma Inc in one report.

$ $295
Buy Report View Sample
  • Save hours of research time and resources with
    our up-to-date Lumos Pharma Inc Strategy Report

  • Understand Lumos Pharma Inc position in the market,
    performance and strategic initiatives.

  • Gain competitive edge and increase your
    chances of success

Back to companies

Lumos Pharma Inc: Overview

Select Item

Lumos Pharma Inc (Lumos Pharma), formerly NewLink Genetics Corp is a clinical-stage biopharmaceutical company that focuses on the development and commercialization of new therapies for the treatment of unmet medical needs of rare diseases. It’s lead investigating candidate, LUM-201 (ibutamoren) is an oral growth hormone stimulating therapy for the treatment of pediatric growth hormone deficiency (PGHD), turner syndrome, children born small for gestational age (SGA), and other rare endocrine disorders. Lumos Pharma is headquartered in Austin, Texas, the US.

 Gain a 360-degree view of Lumos Pharma Inc and make more informed decisions for your business Gain a 360-degree view of Lumos Pharma Inc and make more informed decisions for your business Find out more
Headquarters United States of America
Address 4200 Marathon Blvd., Suite 200, Austin, Texas, 78756
Website lumos-pharma.com
Telephone 1 512 2152630
No of Employees 33
Industry Pharmaceuticals and Healthcare
Ticker Symbol & Exchange LUMO (NASD)
Revenue (2022) $2.1M 34.7% (2022 vs 2021)
EPS XYZ
Net Income (2022) XYZ -9.6% (2022 vs 2021)
Market Cap* $20.4M
Net Profit Margin (2022) XYZ 18.6% (2022 vs 2021)
* As of and is in US$
View Lumos Pharma Inc financials
Gain access to our premium signals and make informed decisions for your business Gain access to our premium signals and make informed decisions for your business Find out more

Lumos Pharma Inc premium industry data and analytics

60+

Clinical Trials

Determine Lumos Pharma Inc go-to-market proposition and gain insight into the company’s clinical operations, recruitment, and trial strategy.

30+

Catalyst Calendar

Proactively evaluate Lumos Pharma Inc’s catalyst impacts to stay ahead of the competition & improve corporate planning. Bolster business development with timely opportunities.

20+

Pipeline Drugs

Identify which of Lumos Pharma Inc’s products will be commercialized, helping you to better contend with shifting product portfolios, and allowing you to stay one step ahead of the market.

20+

Insights

Remove risk and uncertainty, gain a competitive edge and secure actionable leads with access to company-related investigative journalist content.

4

Regulatory Milestones

Track drug and patent expiries along with geographies impacted.

Products and Services

Products
Pipeline:
LUM-201:
Turner Syndrome
XYZ
XYZ
XYZ
Understand Lumos Pharma Inc portfolio and identify potential areas for collaboration Understand Lumos Pharma Inc portfolio and identify potential areas for collaboration Find out more
Image for loader

Competitor Comparison

Key Parameters Lumos Pharma Inc F. Hoffmann-La Roche Ltd Merck & Co Inc Theratechnologies Inc Aceragen Inc
Headquarters United States of America Switzerland United States of America Canada United States of America
City Austin Basel Kenilworth Montreal Durham
State/Province Texas - New Jersey Quebec North Carolina
No. of Employees 33 103,605 72,000 89 26
Entity Type Public Public Public Public Private
Benchmark the company against the market with exclusive information on key competitors Benchmark the company against the market with exclusive information on key competitors Find out more
Chart Financial activity with access to more key stats Chart Financial activity with access to more key stats Find out more
Executives
Name Position Board Since Age
Richard J. Hawkins Chief Executive Officer; Chairman Executive Board 2020 74
Lori D. Lawley Chief Financial Officer Senior Management 2021 39
John McKew Ph.D. President; Chief Operating Officer; Chief Scientific Officer Senior Management 2020 58
Pisit Pitukcheewanont, MD Chief Medical Officer Senior Management 2024 -
Aaron Schuchart Chief Business Officer Senior Management 2020 -
Non Dignissim Eros Proin vel Convallis 2024 XY
Non Dignissim Eros Proin vel Convallis 2024 XY
Non Dignissim Eros Proin vel Convallis 2024 XY
Gain insight into Lumos Pharma Inc key executives to enhance your sales strategy Gain insight into Lumos Pharma Inc key executives to enhance your sales strategy Find out more
Still looking?

Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.

Explorer

Access more premium companies when you subscribe to Explorer

Get in touch about GlobalData Company reports

Contact the team or request a demo to find out how our data can drive your business forward